Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 1998

View Archived Issues

Antiallergic efficacy of dual-action compound demonstrated in preclinical models

Company Profile: Athersys

Novel AIDS therapy shows promise

Atrix receives CE mark approval for Atrisorb; ISO 9001 certification granted

Nastech licenses nasal scopolamine to Schwarz

Eisai in-licenses antiobesity drug for Japanese market

Photofrin enters phase III testing for new indication

New use approved for Lescol

U.S. marketing application submitted for AD-32

PDE IV/TNF production inhibitors claimed by Schering AG for MS

Novartis discloses HIV protease inhibitors with excellent pharmacodynamic profile

Vertex describes new IMPDH inhibitors

Serotonergic agents prepared at Merck KGaA as potential antidepressants/anxiolytics

Merck & Co. describes new thrombin inhibitors

Novel ET antagonists claimed by BASF

Agents with affinity for 5-HT2 receptors under development at Janssen

Takeda obtains remaining HMR stake in French joint venture

Abgenix and Pfizer collaborate on XenoMouse antibodies

AHC-52, a new dihydropyridine with cardioprotective effects

Pharmacological profile of parenteral ET antagonist for SAH described by Roche

Preclinical and preliminary clinical results reported for CS-834

IC-351 advances to phase II for MED

DuPont Merck, Signal collaborate on HCV and HIV research

Abbott in-licenses lipid-lowering drug from Fournier

Korean researchers discover new PLC and PI turnover inhibitor from fungal strain

Indian researchers describe new anticancer agent

Carbapenems with enhanced antipseudomonal activity and stability

Genzyme Transgenics breakthrough could lead to potential malaria vaccine

IMPDH inhibitor VX-497 advances to clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...